FY2025 Earnings Estimate for VKTX Issued By Leerink Partnrs

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Viking Therapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the biotechnology company will post earnings of ($1.74) per share for the year, down from their previous forecast of ($1.65). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ FY2026 earnings at ($2.30) EPS, FY2027 earnings at ($3.81) EPS and FY2028 earnings at ($1.11) EPS.

Viking Therapeutics (NASDAQ:VKTX) last announced its earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same period last year, the firm earned ($0.25) earnings per share.

Other research analysts also recently issued reports about the stock. B. Riley reiterated a “buy” rating and issued a $96.00 price target (down from $109.00) on shares of Viking Therapeutics in a research report on Friday. Citigroup began coverage on Viking Therapeutics in a report on Friday. They issued a “neutral” rating and a $38.00 target price on the stock. Raymond James boosted their price target on Viking Therapeutics from $122.00 to $125.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Thursday, February 6th. Finally, Piper Sandler lowered their price objective on Viking Therapeutics from $74.00 to $71.00 and set an “overweight” rating on the stock in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.92.

Viking Therapeutics Trading Down 7.3 %

VKTX opened at $30.17 on Monday. The company’s 50 day moving average is $39.63 and its 200 day moving average is $53.68. The company has a market cap of $3.36 billion, a price-to-earnings ratio of -30.17 and a beta of 0.90. Viking Therapeutics has a 12-month low of $29.82 and a 12-month high of $99.41.

Hedge Funds Weigh In On Viking Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Signaturefd LLC lifted its holdings in shares of Viking Therapeutics by 16.2% in the 3rd quarter. Signaturefd LLC now owns 1,351 shares of the biotechnology company’s stock worth $86,000 after acquiring an additional 188 shares during the last quarter. Stone House Investment Management LLC increased its stake in Viking Therapeutics by 66.7% in the third quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 200 shares during the period. Keudell Morrison Wealth Management lifted its position in shares of Viking Therapeutics by 5.9% during the third quarter. Keudell Morrison Wealth Management now owns 4,306 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 241 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Viking Therapeutics by 124.6% in the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 243 shares during the last quarter. Finally, S.A. Mason LLC lifted its holdings in Viking Therapeutics by 20.0% during the 4th quarter. S.A. Mason LLC now owns 1,800 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Insiders Place Their Bets

In related news, COO Marianna Mancini sold 54,215 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $42.75, for a total value of $2,317,691.25. Following the sale, the chief operating officer now directly owns 374,134 shares in the company, valued at approximately $15,994,228.50. The trade was a 12.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Brian Lian sold 194,490 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $8,314,447.50. Following the transaction, the chief executive officer now owns 2,366,570 shares of the company’s stock, valued at $101,170,867.50. This represents a 7.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 299,014 shares of company stock worth $12,782,849 in the last three months. 4.70% of the stock is owned by company insiders.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.